Skip to main content
. 2018 Nov 12;7(11):84. doi: 10.1038/s41389-018-0095-x

Fig. 2. Ikaros binding sites at ARID5B promoter in B-ALL cells were determined by ChIP-seq (a).

Fig. 2

b, c Ikaros binding at ARID5B promoter was validated by qChIP assay in b ALL cell lines and (c) primary ALL cells. Graphed data are the mean ± SD of triplicates representative of one of 3 independent experiments (a, b) or 3 patient samples (c). ***p < 0.001